Skip to main content
Premium Trial:

Request an Annual Quote

Canary Molecular POC SARS-CoV-2 Test Nabs CE Mark

NEW YORK – Molecular diagnostic company Canary Global announced on Tuesday that it received CE marking last week for its DigiGene COVID-19 Rapid Molecular Test Kit. 

The self-collected saliva test uses biosensors to return positive results in approximately five minutes and negative results in less than 20 minutes, the company said in a statement. The kit can process four test samples simultaneously and is intended for use in point-of-care settings.

The testing kit has a handheld reusable digital reader and disposable test cartridges that use loop-mediated isothermal amplification and smart sensors to detect SARS-CoV-2 RNA in saliva, oral, and nasal passages, along with cloud-based analytics to report results to a smartphone. The test has delivered 95 percent sensitivity and 98 percent specificity in both symptomatic and asymptomatic people with SARS-CoV-2, including cases with variants, the company said.

Canary's test is also being submitted to the US Food and Drug Administration for Emergency Use Authorization for at-home use and point-of-care use, the company added. It noted that it plans to gear up production to supply "millions of units" over the coming months.

"The ability to detect SARS-CoV-2 early, before the onset of symptoms, or those who never develop symptoms, will help drastically reduce household and community transmission," Canary Global CEO Raj Reddy said in a statement. "And in the face of therapies that are currently being developed, a faster diagnosis will make all the difference in controlling and stopping the spread of COVID."

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.